A phase 2/3 multicenter trial evaluating safety and efficacy of a new mucoadhesive gemcitabine suspension for ablation of upper tract urothelial carcinoma. ABLE-22: Safety and efficacy evaluation of ...

Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle-invasive bladder cancer (MIBC). Mutations in DNA damage repair genes are ...

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible muscle-invasive bladder cancer. Patients with cisplatin-eligible ...

An analysis of pre-treatment tumor specimens from 105 patients with localized muscle-invasive bladder cancer found that the presence of a mutation in any one of three genes, all known to be involved ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) ...

The most common adverse events reported in the neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin arm were pruritus, alopecia, diarrhea, fatigue and anemia. No new safety signals were ...

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...

S.M. Gilbert is a fellow in Urologic Oncology in the Department of Urology atthe University of Michigan, MI. C.T. Lee is an Associate Professor of Urologyat the University of Michigan, MI, USA, where ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

The U.S. Food and Drug Administration (FDA) on Friday approved injectable and intravenous versions of Merck’s (MRK) ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial Seventy patients were enrolled, 33 (47%) had a mutation, and ...